American Society of Hirudotherapy

Subjective Tinnitus

Investigational for tinnitus; small non-randomized studies, mostly Russian, report less ear noise, and no study using the Tinnitus Handicap Inventory was identified.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for tinnitus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for subjective tinnitus is investigational.
What evidence exists?
Tier C (investigational). There are no randomized controlled trials; the clinical evidence is a few small non-randomized studies, mostly from Russia, one comparing 38 patients given leeches plus drugs with 35 given drugs alone (Senchukova 2013); two books also describe an older study that included a comparison group (see “What the books describe” below). Tinnitus has high placebo response. Evidence-based management focuses on hearing-loss correction (hearing aids), cognitive-behavioral therapy, tinnitus retraining therapy, and sound therapy. Pulsatile tinnitus is a separate condition that requires vascular workup.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment (placement around the ear, mastoid, or upper neck)
  • Bruising and tenderness near the ear and neck for 5 to 10 days
  • Itching and irritation at bite sites for days to weeks
  • Local skin infection or, rarely, Aeromonas infection (particular concern near ear canal)
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of tinnitus or new dizziness for 1 to 2 days
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
Who should not consider this
  • Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
  • Patients with hemophilia or other bleeding disorders
  • Patients with anemia
  • Patients with pulsatile tinnitus (needs vascular workup, not leech therapy)
  • Patients with unilateral tinnitus not yet evaluated by ENT/MRI (rule out acoustic neuroma)
  • Patients with active outer or middle ear infection
  • Patients with a weakened immune system
  • Patients who have not had audiologic evaluation and hearing aid fitting
  • People with an active infection at the planned application site
What to ask your clinician
  • Have I had an audiogram and ENT evaluation?
  • Have I had imaging (MRI) if my tinnitus is unilateral, pulsatile, or associated with neurologic symptoms?
  • Have I been offered hearing aids (if hearing loss), CBT, tinnitus retraining, or sound therapy?
  • What evidence supports leech therapy for tinnitus specifically?
  • What is the realistic chance of benefit, given high placebo response?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the cost?
When to seek urgent care
  • Sudden hearing loss in one or both ears (sudden sensorineural hearing loss is an emergency)
  • New severe vertigo, gait imbalance, weakness, numbness, or speech change
  • Spreading redness, warmth, pus, or red streaks near the ear (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Tinnitus that becomes pulsatile (new vascular workup needed)
  • Severe distress with suicidal ideation (tinnitus distress can be serious)

What this does NOT mean

  • This is not FDA-cleared for tinnitus.
  • Small non-randomized studies and case reports do NOT establish efficacy beyond placebo, especially in tinnitus where placebo response is high.
  • Mechanism rationale (venous decongestion, local anti-inflammation) does NOT establish clinical efficacy.
  • Leech therapy will NOT cure tinnitus and does NOT address underlying causes.
  • Leech therapy is not a substitute for ENT evaluation, hearing-aid fitting, or behavioral therapies.

Clinical Profile

Category
ENT
ICD-10
H93.11, H93.12, H93.13, H93.19
Safety tier
Low

Evidence Summary

The clinical evidence for leech therapy in tinnitus consists of a few small, mostly Russian, non-randomized studies. Seleznev et al. (1992, ORL; PMID 1584585) treated tinnitus from inner-ear disease, acute external otitis and chronic otitis media with medicinal leeches or with diluted leech saliva given by microelectrophoresis; the saliva route was about 25-30% less effective than leeches (the Baskova and Isakhanyan 2004 monograph gives 273 patients across the three diagnoses; the tinnitus subgroup size is not stated in the abstract). Senchukova and Nikulina (2013, Fundamental'nye Issledovaniya) compared 38 patients with vascular sensorineural hearing loss and tinnitus given leeches plus drug therapy with 35 given drug therapy alone: tinnitus disappeared in 20 of 38 (52.6%) versus 6 of 35 (17.1%); randomization and blinding were not described. Zaitseva (2012; PMID 23268258) reported that tympanophonia (indexed as tinnitus) fell by about one third in 9 of 10 patients given leeches within a 56-patient retrospective series, and Morozova and Aksenova (2009; PMID 19738593) reported less ear noise with leeches in peripheral cochleovestibular disorders of vascular origin. No randomized trial and no study using the Tinnitus Handicap Inventory was identified, so any use remains investigational. Where attempted, the mechanism is speculative, involving cervicogenic/somatosensory or local vascular factors. Objective tinnitus (audible pulsatile tinnitus from vascular pathology or glomus tumor) requires imaging workup and is not an indication. ENT consultation is essential before any treatment.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan report that in the 1990 methodological guidelines Seleznev and Shchetinina included, among other things, noises in the ear in chronic neuritis of the auditory nerves among the indications for including hirudotherapy in the complex of treatment measures for diseases of the ear, throat and nose[B1].
  • The same passage says that the results of combined treatment with hirudotherapy were satisfactory and that on audiometry the intensity of the noise decreased; whose observations these are (those of the guidelines or of the authors of the book), how many patients there were and which diseases from this list the description refers to is not clear from the text[B1].
  • They also describe a study by Seleznev et al. (1992) in 273 patients with acute outer ear inflammation (otitis externa), chronic middle ear inflammation (otitis media) and tinnitus, in which hirudotherapy was compared with introducing leech saliva into the skin (microelectrophoresis) and with the usual drug treatment: according to these data, saliva given this way worked less well than the leeches, but the authors stipulate that their figures are very approximate, and how many of the 273 had tinnitus and what the result was in the control group is not clear from the text[B1].
  • Michalsen, in the chapter on the scientific basis, writes about a study by Baskova’s team in Moscow in 273 patients (in his reference list this is the work of Seleznev et al., 1992): by his account, in otitis externa and tinnitus hirudotherapy showed significant superiority in alleviating the symptoms (by which measure and over which of the two other groups is not stated in the text), and in otitis media it had no noticeable effect; he advises interpreting the results, especially in tinnitus, with caution[B3].
  • Flecken and Michalsen, in the chapter on indications, write that the available data on hirudotherapy in tinnitus are not sufficient for an objective assessment of the treatment response (the syndrome is difficult to treat and its cause is unclear), that the mechanism of action is unclear and that unspecific effects (a placebo effect) must be taken into account; but since the treatment options are limited, they consider a treatment attempt with leeches justified in severe cases[B3].
  • On sudden hearing loss, Flecken and Michalsen write only that hirudotherapy can be considered, although no published scientific data on this exist yet, and how this compares with usual treatment is not stated in that paragraph; Baskova and Isakhanyan do not write about sudden hearing loss (of the ear diseases, their closing summary names inflammatory diseases of the ear and chronic sensorineural hearing loss)[B1][B3].
  • Among the contraindications to hirudotherapy, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias and concurrent prescription of anticoagulants (their list is longer); Flecken and Michalsen, in the chapter on contraindications, regard congenital or acquired hemophilia and taking anticoagulants (Marcumar, warfarin, heparin, heparinoids) as an absolute contraindication, and in anemia, in their words, treatment involving blood removal is generally contraindicated[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Objective pulsatile tinnitus (must rule out structural cause)
  • Acute otitis media or externa
  • Untreated hearing loss (audiology referral first)
  • Preauricular, mastoid, or facial placement (facial nerve and arterial risk)
  • Severe anxiety or depression where CBT or psychiatry referral is primary

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.